Loading...

171 posters, 10 topics, 5 sessions, 690 authors, 211 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

American Association of Plastic Surgeons Meeting 2022

April 9 - 12 | San Diego, California

American Association of Plastic Surgeons Meeting 2022 banner

P17

Are Immunologic Responses To Implants Translated From Capsule To Breast Tissue? An Analysis Of Immunophenotypes In Breast Revision Versus Implant Naïve Breast Tissue

Poster Presenter

Megan Fracol

Part of Topic

Basic Science Research

Are Immunologic Responses To Implants Translated From Capsule To Breast Tissue? An Analysis Of Immunophenotypes In Breast Revision Versus Implant Naïve Breast Tissue
Ramsey Timmerman, BS, Sophia Allison, BASc, Megan Fracol, MD, David Dolivo, Ph.D., Seok Hong, Ph.D., Robert Galiano, MD, FACS, John Y.S. Kim, MD, FACS.
Northwestern University, Chicago, IL, USA.

PURPOSE: Women with cosmetic breast implants have lower rates of future breast cancer. We hypothesized that peri-implant inflammation may induce breast cancer immunosurveillance to protect against breast cancer. The capsule inflammatory milieu has been well-characterized, but whether this inflammatory response extends beyond capsule to the breast parenchyma has not been studied.
METHODS: Breast tissue was collected from patients undergoing first time breast augmentation (n=30) and secondary breast revision (n=24). Total RNA was isolated and converted to complementary DNA. qRT-PCR was performed using iTaq Universal SYBR Green Supermix (Bio-Rad). Gene specific targets were designed for CD4+ (Th1, Th2, Th17, Tfh, Treg), CD8+, and B cells. Immune target gene expression levels were normalized by GAPDH levels and expressed as fold change relative to the implant naïve group. Groups were compared with unpaired t-tests using Graphpad Prism v9.1.2.
RESULTS: qRT-PCR data showed elevated expression of genes specific to Th17 cells and B cells in revision breast tissue (implant exposed group). Fold change for gene expression of the implant exposed group relative to the implant naïve group was found to be 2.00x for IL17A (p=0.0148), 1.72x for RORγt (p=0.0180), 1.68x for RORα (p=0.0318), 2.91x for BATF (p=0.0008), 1.76x for CD138 (p=0.0340), and 2.60x for CD19 (p=0.0338). Gene expression levels were not significantly different between groups for Th1, Th2, Tfh, Treg, and CD8+ T cell genes.
CONCLUSION: Peri-implant inflammatory changes extend beyond capsule to breast parenchyma. Further studies will elucidate whether these immune cells serve in a cancer immunosurveillance capacity.

 

American Association of Plastic Surgeons Meeting 2022 » banner
Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.